CAF, cancer-associated fibroblast; HDAC inhibitor, histone deacetylase inhibitor; MEK inhibitor, mitogen-activated protein kinase inhibitor; CDK inhibitor, cyclin-dependent kinase inhibitor; EGFR inhibitor, epidermal growth factor receptor inhibitor; VEGF inhibitor, vascular endothelial growth factor inhibitor; CAR-T cell therapy, chimeric antigen receptor T cell therapy. This evidence concerns the gene WNK2 and cancer.